Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary
Asian Pacific journal of cancer prevention : APJCP(2019)
摘要
Background: Neuroendocrine tumors (NETs) are rare tumors that can originate from any part of the body. Often,
imaging or exploratory surgery can assist in the identification of the tumor primary site, which is critical to the
management of the disease. Neuroendocrine tumors (NETs) of unknown primary constitute approximately 10-15%
of all NETs. Determining the original site of the tumor is critical to providing appropriate and effective treatment.
Methods: We performed a retrospective review of neuroendocrine tumors at our institution between 2012 and 2016
using a 92-gene cancer ID analysis. Results: 56 patients with NETs of unknown primary were identified. Samples
for 38 of the 56 underwent the 92-gene cancer ID analysis. The primary site of the tumor was identified with >95%
certainty in 35 of the 38 patients. Conclusion: The 92-gene cancer ID analysis identified a primary site in 92% of our
NETs study cohort that previously had been unknown. The results have direct implications on management of patients
with regard to FDA-approved treatment options.
更多查看译文
关键词
Neuroendocrine tumor,tumor of unknown primary,92-gene cancer ID assay
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要